MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 12/19/17 SECTION: MEDICINE LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

Similar documents
ENDOBRONCHIAL ULTRASOUND FOR DIAGNOSIS AND STAGING OF LUNG CANCER

PANCREATIC ISLET TRANSPLANT

GENETIC TESTING FOR PREDICTING RISK OF NONFAMILIAL BREAST CANCER

LARTRUVO (olaratumab)

GENETIC TESTING FOR TAMOXIFEN TREATMENT

HEMATOPOIETIC CELL TRANSPLANTATION FOR EPITHELIAL OVARIAN CARCINOMA

IMMUNE CELL FUNCTION ASSAY

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 10/04/17 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

GENETIC TESTING FOR KRAS, NRAS AND BRAF VARIANT ANALYSIS IN METASTATIC COLORECTAL CANCER

DRUG TESTING IN PAIN MANAGEMENT AND SUBSTANCE USE DISORDER(S) TREATMENT

ALPHA1-PROTEINASE INHIBITORS

MOLECULAR TESTING IN THE MANAGEMENT OF PULMONARY NODULES

ORAL IMPLANT PROCEDURES

RADIOFREQUENCY ABLATION OF PRIMARY OR METASTATIC LIVER TUMORS

INTRAPERITONEAL CHEMOTHERAPY, CYTOREDUCTION

FECAL ANALYSIS IN THE DIAGNOSIS OF INTESTINAL DYSBIOSIS

NUTRIENT OR NUTRITIONAL PANEL TESTING

ENTYVIO (vedolizumab)

NOVEL BIOMARKERS IN RISK ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR DISEASE

PROTEOMIC TESTING FOR SYSTEMIC THERAPY IN NON-SMALL-CELL LUNG CANCER

APOKYN (apomorphine hydrochloride)

BLINCYTO (blinatumomab)

CONTINUOUS OR INTERMITTENT GLUCOSE MONITORING IN INTERSTITIAL FLUID

TREATMENTS FOR GAUCHER DISEASE

STELARA (ustekinumab)

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

GENETIC TESTING FOR FANCONI ANEMIA

MYLOTARG (gemtuzumab ozogamicin)

MULTIMARKER SERUM TESTING RELATED TO OVARIAN CANCER

GATTEX (teduglutide [rdna origin])

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

RELISTOR (methylnaltrexone bromide) INJECTION FOR SUBCUTANEOUS USE

GENETIC TESTING FOR HEREDITARY HEARING LOSS

CIMZIA (certolizumab pegol)

TYMLOS (abaloparatide)

NEGATIVE PRESSURE WOUND THERAPY

OPTICAL COHERENCE TOMOGRAPHY (OCT) OF THE MIDDLE EAR

SOMATULINE DEPOT (lanreotide acetate)

RADIOFREQUENCY ABLATION OF MISCELLANEOUS SOLID TUMORS EXCLUDING LIVER TUMORS

BRINEURA (cerliponase alfa)

PARSABIV (etelcalcetide)

CARDIOVASCULAR RISK PANELS

HEMATOPOIETIC CELL TRANSPLANTATION FOR PRIMARY AMYLOIDOSIS

INTRACAVITARY BALLOON BRACHYTHERAPY FOR MALIGNANT AND METASTATIC BRAIN TUMORS

GENETIC TESTING FOR MARFAN SYNDROME, THORACIC AORTIC ANEURYSMS AND DISSECTIONS AND RELATED DISORDERS

INTRAVITREAL IMPLANTS

BALLOON OSTIAL DILATION FOR TREATMENT OF CHRONIC SINUSITIS

GENETIC TESTING FOR NEUROFIBROMATOSIS

VYXEOS (daunorubicin and cytarabine)

GENE EXPRESSION PROFILING AND PROTEIN BIOMARKERS FOR PROSTATE CANCER MANAGEMENT

INTERSPINOUS FIXATION (FUSION) DEVICES

PERJETA (pertuzumab) FOR TREATMENT OF MALIGNANCIES

GENETIC TESTING WITH MOLECULAR PANEL TESTING OF CANCERS TO IDENTIFY TARGETED THERAPIES

DERMATOLOGIC APPLICATIONS OF PHOTODYNAMIC THERAPY

TYSABRI FOR CROHN S DISEASE

GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER SYNDROME BRCA1 BRCA2

BONIVA (ibandronate sodium)

AUTOLOGOUS CHONDROCYTE IMPLANTATION FOR FOCAL ARTICULAR CARTILAGE LESIONS

DEEP BRAIN STIMULATION

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

GENETIC TESTING FOR FLT3, NPM1 AND CEBPA VARIANTS IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

INJECTABLE BULKING AGENTS FOR THE TREATMENT OF URINARY AND FECAL INCONTINENCE

TRANSMYOCARDIAL REVASCULARIZATION

ELECTROMYOGRAPHY (EMG) AND NERVE CONDUCTION STUDIES (NCS)

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

NASAL AIRWAY EVALUATION Acoustic Reflex Technology Acoustic Rhinometry Optical Rhinometry Rhinomanometry Sleep Sonography

BIVENTRICULAR PACEMAKER (CARDIAC RESYNCHRONIZATION THERAPY) FOR THE TREATMENT OF HEART FAILURE

DYNAMIC SPINAL VISUALIZATION

PERCUTANEOUS BALLOON KYPHOPLASTY, RADIOFREQUENCY KYPHOPLASTY, AND MECHANICAL VERTEBRAL AUGMENTATION

PERCUTANEOUS TIBIAL NERVE STIMULATION

HEMATOPOIETIC CELL TRANSPLANTATION FOR HODGKIN LYMPHOMA

PERCUTANEOUS TRANSCATHETER CLOSURE OF PARAVALVULAR LEAK

STRENSIQ (asfotase alfa)

GENETIC TESTING FOR TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC)

PERCUTANEOUS TIBIAL NERVE STIMULATION

H.P. ACTHAR GEL (repository corticotropin injection)

HEMATOPOIETIC CELL TRANSPLANTATION FOR SOLID TUMORS OF CHILDHOOD

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 11/14/17 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

BREAST RECONSTRUCTION/REMOVAL AND REPLACEMENT OF IMPLANTS

HEMATOPOIETIC CELL TRANSPLANTATION FOR CHRONIC MYELOID LEUKEMIA

INTRAOPERATIVE RADIATION THERAPY

ACTEMRA (tocilizumab)

LIMB COMPRESSION DEVICES FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS

KYMRIAH (tisagenlecleucel)

ELECTRIC TUMOR TREATMENT FIELDS

ALPHA-FETOPROTEIN-L3 FOR DETECTION OF HEPATOCELLULAR CANCER

COSENTYX (secukinumab)

LUXTURNA (voretigene neparovec-rzyl)

VESTIBULAR FUNCTION TESTING

Department of Origin: Integrated Healthcare Services. Approved by: Chief Medical Officer Department(s) Affected: Date approved: 01/10/17

YESCARTA (axicabtagene ciloleucel)

DECISIONDx BIOMARKER TESTS

MEASUREMENT OF EXHALED NITRIC OXIDE AND EXHALED BREATH CONDENSATE

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

MYALEPT (metreleptin)

RADIOFREQUENCY ABLATION OR CRYOABLATION FOR ESOPHAGEAL DISORDERS

HEMATOPOIETIC CELL TRANSPLANTATION FOR GENETIC DISEASES AND ACQUIRED ANEMIAS

COMPLEMENTARY AND ALTERNATIVE MEDICINE

Transcription:

MEDICAL FOODS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Medical Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines. The section identified as Description defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage. The section identified as Criteria defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational. State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity. Medical Coverage Guidelines are subject to change as new information becomes available. For purposes of this Medical Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable. BLUE CROSS, BLUE SHIELD and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ. Description: Medical foods are defined as: Modified low protein foods or metabolic formulas, generally available only under the supervision and direction of a physician or a registered nurse practitioner, that are medically necessary for the treatment of an inherited metabolic disorder (also referred to as an inborn error of metabolism) of amino acid, carbohydrate or fat metabolism included in the newborn screening program as required by law, that must be consumed throughout life, and without which the individual may suffer serious mental or physical impairment, or An amino acid-based formula that is ordered by a physician or a registered nurse practitioner for an individual diagnosed with an eosinophilic gastrointestinal disorder (EGID) O648.6.docx Page 1 of 5

Criteria: COVERAGE FOR MEDICAL FOODS IS DEPENDENT UPON BENEFIT PLAN LANGUAGE. REFER TO MEMBER S SPECIFIC BENEFIT PLAN BOOKLET TO VERIFY BENEFITS. Medical foods for the treatment of inherited metabolic disorders are considered eligible for coverage based on the benefit plan allowance with documentation of ALL of the following: 1. Diagnosis of ANY of the following inherited metabolic disorders included in the newborn screening program: 3-hydroxy-3-methylglutaric aciduria (HMG) 3-methylcrotonyl CoA carboxylase (3-MCC) deficiency Argininosuccinic acidemia Beta-ketothiolase deficiency (BKD) Biotinidase deficiency Citrullinemia Galactosemia Glutaric acidemia-type 1 (GA-1) Homocystinuria Isovaleric acidemia (IVA) Long chain 3-hydroxy acyl-coa dehydrogenase deficiency Maple syrup urine disease Medium chain acyl-coa dehydrogenase deficiency Methylmalonic acidemia (Cbl A, B) Methylmalonic acidemia (mutase deficiency) Multiple carboxylase deficiency Phenylketonuria (PKU) Propionic acidemia (propionyl CoA carboxylase deficiency) Trifunctional protein deficiency Tyrosinemia Very long-chain acyl-coa dehydrogenase deficiency (VLCADD) 2. The medical food is prescribed or ordered and monitored under the supervision of a physician or nurse practitioner 3. There is risk of mental or physical impairment without the use of the medical food O648.6.docx Page 2 of 5

Criteria: (cont.) Medical foods for the treatment of Eosinophilic Gastrointestinal Disorders (EGID) are considered eligible for coverage based on the benefit plan allowance and documentation of ALL of the following: 1. Diagnosis of EGID confirmed by endoscopy and biopsy 2. Individual is under the continuous supervision of a licensed physician or a registered nurse practitioner 3. The medical food is ordered by a treating provider 4. There is a risk of mental or physical impairment without the use of the medical food Medical foods for all other indications not previously listed are a benefit plan exclusion and not eligible for coverage. Supplementation of foods, formulas, vitamins or nutrients that are available over the counter (OTC) are a benefit plan exclusion and not eligible for coverage. Resources: 1. Arizona Administrative Code. section R9-13-202. Received 04/23/2013. 2. Arizona Revised Statutes. sections 20-826, 20-826.03, 20-1057, 20-1057.10, 20-2332, 20-2327, 36-694. 3. Baumgartner ER ST. Multiple carboxylase deficiency: inherited and acquired disorders of biotin metabolism. International Journal for Vitamin and Nutrition Research.67(5):377-384. 4. Gillingham MB, Connor WE, Matern D, et al. Optimal dietary therapy of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Mol Genet Metab. Jun 2003;79(2):114. 5. Marc P Difazio RGD. Biotinidase Deficiency. April 21, 2004. O648.6.docx Page 3 of 5

Non-Discrimination Statement: Blue Cross Blue Shield of Arizona (BCBSAZ) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability or sex. BCBSAZ provides appropriate free aids and services, such as qualified interpreters and written information in other formats, to people with disabilities to communicate effectively with us. BCBSAZ also provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services, call (602) 864-4884 for Spanish and (877) 475-4799 for all other languages and other aids and services. If you believe that BCBSAZ has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability or sex, you can file a grievance with: BCBSAZ s Civil Rights Coordinator, Attn: Civil Rights Coordinator, Blue Cross Blue Shield of Arizona, P.O. Box 13466, Phoenix, AZ 85002-3466, (602) 864-2288, TTY/TDD (602) 864-4823, crc@azblue.com. You can file a grievance in person or by mail or email. If you need help filing a grievance BCBSAZ s Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Avenue SW., Room 509F, HHH Building, Washington, DC 20201, 1 800 368 1019, 800 537 7697 (TDD). Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html Multi-Language Interpreter Services: O648.6.docx Page 4 of 5

Multi-Language Interpreter Services: (cont.) O648.6.docx Page 5 of 5